TICKERNERD
Menu
SPTXHealthcare · Biotechnology

SPTX Stock Forecast: Seaport Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$24
+1.12% on the day

The 6 Wall Street analysts covering Seaport Therapeutics, Inc. hold a median 12-month price target of $35 — +44.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.3B
Ticker Nerd rank
1 / 100
Median analyst target
$35
Analysts covering
6
Total return, dividends reinvested
1W
+0.4%
1M
+15.8%
From high
−0.5%
From low
+59.4%
$15
$24
Range since 1 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

SPTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Seaport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
42
Revisions
29
Momentum
20
Issuance
10
Value
9
Growth
8
Accruals
8
Quality
4
Volatility
4

Size (42): Smaller than most of the companies we track.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SPTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SPTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 1 May 2026Adjusted close, US dollars
$10$20$30$40$50May 26Jun 26Jul 26Aug 26SPTXHigh $50Median $35Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $30Median $35High $50

The green dot is the last close — the median target sits +44.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
4 Aug 2026HC Wainwright & Co.ReiteratesBuy—
4 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
15 July 2026HC Wainwright & Co.InitiatesBuy$50
15 July 2026HC Wainwright & Co.InitiatesBuy—
26 May 2026CitigroupInitiatesBuy—
26 May 2026CitigroupInitiatesBuy$35
26 May 2026JP MorganInitiatesOverweight$42
26 May 2026JP MorganInitiatesOverweight—
26 May 2026Leerink PartnersInitiatesOutperform$35
26 May 2026Leerink PartnersInitiatesOutperform—
26 May 2026StifelInitiatesBuy$30
26 May 2026StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SPTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Seaport Therapeutics, Inc. (SPTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−12.6×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
−11.2×

Cheaper than 98% of US stocks

EV / EBITDA
−7.2×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
80.9%

Higher than 95% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SPTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SPTXSeaport Therapeutics, Inc.$1.3B
1
MNKDMannKind Corp.$1.3B
34
MLTXMoonLake Immunotherapeutics$1.3B
15
DRTSAlpha Tau Medical Ltd.$1.3B
17
MGTXMeiragtx Holdings plc$1.3B
83
AKTSAktis Oncology, Inc.$1.3B
2
CGEMCullinan Therapeutics, Inc.$1.3B
71

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Seaport Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SPTX news & analysis

Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation

Seeking Alpha · 11 Aug 2026positive

Seaport Therapeutics is advancing its Glyph platform, which converts clinically validated molecules with poor delivery into patent-protected prodrugs to reduce biological risk. The article details GlyphAllo's Phase 2b BUOY-1 trial in MDD with top-line data expected in H1 2027 and focus on anxious distress subpopulations, plus GlyphAgo's strong Phase 1 PK data and Phase 2a in GAD slated for H2 2026 followed by registration-enabling studies.

Why it matters — A SPTX watcher would care because the article highlights the platform's two layers of validation and outlines clear upcoming clinical milestones for both GlyphAllo and GlyphAgo programs.

FAQ

Frequently asked questions about SPTX stock

What is the SPTX stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Seaport Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SPTX stock a buy right now?

Of the 6 analysts covering Seaport Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seaport Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SPTX?

As at 22 Aug 2026, Seaport Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (42 of 100).

Will SPTX stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +44.0% from the last close, and Ticker Nerd's factor model ranks Seaport Therapeutics, Inc. 1 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SPTX stock forecast for 2030?

No analyst covering Seaport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $50 over the next 12 months.

What does Seaport Therapeutics, Inc. do?

Seaport Therapeutics, Inc. is a clinical-stage biotechnology company focused on inventing and developing novel oral medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.

What is the latest news on SPTX?

The most recent item we track (Seeking Alpha, 11 Aug 2026): "Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation". Seaport Therapeutics is advancing its Glyph platform, which converts clinically validated molecules with poor delivery into patent-protected prodrugs to reduce biological risk. The article details GlyphAllo's Phase 2b BUOY-1 trial in MDD with top-line data expected in H1 2027 and focus on anxious distress subpopulations, plus GlyphAgo's strong Phase 1 PK data and Phase 2a in GAD slated for H2 2026 followed by registration-enabling studies.

Company

About Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. is a clinical-stage biotechnology company focused on inventing and developing novel oral medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company employs its proprietary Glyph platform to address limitations of clinically validated mechanisms, such as high first-pass metabolism, low bioavailability, and side effects, enabling innovative therapies with established efficacy and safety profiles. Seaport Therapeutics targets the neuropsychiatry sector within pharmaceuticals and biotech, aiming to deliver leading treatment options that improve patient outcomes. Its pipeline advances antidepressants and anxiolytics derived from these optimized mechanisms. With a team experienced in neuropsychiatry drug discovery and development, Seaport Therapeutics operates at the intersection of cutting-edge platform technology and targeted therapeutic innovation. Founded in 2024 and headquartered in Boston, Massachusetts, the company plays a role in advancing accessible oral treatments for serious mental health conditions in the competitive biopharmaceutical market.

CEO Ms. Daphne Zohar · 58 employees · United States · https://www.seaporttx.com